Spots Global Cancer Trial Database for renal cell cancer
Every month we try and update this database with for renal cell cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | NCT01021059 | Melanoma Carcinoma, Rena... | rh IL-15 | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers | NCT01079286 | Renal Cell Canc... Cancer | Nelfinavir and ... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | NCT00061178 | Renal Cell Canc... | rhuMAb VEGF (Be... | 18 Years - | Genentech, Inc. | |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| ImmuniCell® in Patients With Advanced Cancers | NCT02459067 | Malignant Melan... Non-small Cell ... Renal Cell Canc... | ImmuniCell® | 18 Years - | TC Biopharm | |
| Urine Proteome of Surgical Patients and Healthy Volunteers | NCT01538823 | Renal Cell Canc... | 18 Years - | Washington University School of Medicine | ||
| Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | NCT01189370 | Renal Cell Canc... | sorafenib | 18 Years - | University of Kansas Medical Center | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) | NCT01598597 | Breast Cancer Colorectal Canc... Non-Small Cell ... Glioblastoma Renal Cell Canc... | 18 Years - | Genentech, Inc. | ||
| Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland | NCT00980213 | Neoplasms Renal Cell Carc... | sunitinib | 18 Years - 85 Years | Tampere University Hospital | |
| Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma | NCT00509704 | Renal Cell Canc... | 18 Years - | Radboud University Medical Center | ||
| DNX-2440 for Resectable Colorectal Liver Metastasis | NCT04714983 | Liver Metastase... Liver Metastasi... Colorectal Canc... Breast Cancer Gastric Cancer Periampullary C... Melanoma Renal Cell Canc... Sarcoma Squamous Cell C... Gastrointestina... | DNX-2440 | 18 Years - | DNAtrix, Inc. | |
| Relationship of Ochratoxin A to Upper Urologic Cancers | NCT00216801 | Transitional Ce... Renal Cell Canc... Testicular Canc... | 18 Years - | Lawson Health Research Institute | ||
| Relationship of Ochratoxin A to Upper Urologic Cancers | NCT00216801 | Transitional Ce... Renal Cell Canc... Testicular Canc... | 18 Years - | Lawson Health Research Institute | ||
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors | NCT06336148 | Solid Tumor | ACTM-838 | 18 Years - | Actym Therapeutics, Inc. | |
| A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients | NCT02599779 | Stage IV Renal ... | Pembrolizumab Stereotactic Bo... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma | NCT00509704 | Renal Cell Canc... | 18 Years - | Radboud University Medical Center | ||
| A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy | NCT01624220 | Spinal Tumor | Spinal SBRT (St... Spinal SBRT (Hi... Gold Seed Impla... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) | NCT02423954 | Advanced Cancer Pancreatic Canc... Renal Cell Canc... Non Small Cell ... Colorectal Carc... Endometrial Uterine | Temsirolimus Irinotecan Irinotecan + ca... nivolumab | 18 Years - | Western Regional Medical Center | |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | NCT05433142 | Clear Cell Rena... | XmAb819 | 18 Years - | Xencor, Inc. | |
| A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | NCT02684006 | Renal Cell Canc... | Avelumab (MSB00... Axitinib (AG-01... Sunitinib | 18 Years - | Pfizer | |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy | NCT00738530 | Renal Cell Canc... | Bevacizumab [Av... Interferon alfa... Placebo | 18 Years - | Hoffmann-La Roche | |
| An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) | NCT01392729 | Renal Cell Canc... | 18 Years - | Hoffmann-La Roche | ||
| Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | NCT04260360 | Renal Cell Carc... Kidney Cancer Adenocarcinoma ... Adenocarcinoma,... Renal Cell Canc... | NanoDoce (steri... | 18 Years - | NanOlogy, LLC | |
| Study of CP-461 in Patients With Advanced Renal Cell Cancer | NCT00036036 | Renal Cell Carc... | CP-461 | 18 Years - | Astellas Pharma Inc | |
| Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response | NCT00694096 | Renal Cell Canc... | Sunitinib | 18 Years - | University of Utah | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| Bevacizumab in Metastatic Renal Cancer | NCT02627144 | Renal Cell Canc... | Bevacizumab Interferon alph... | 18 Years - | Hoffmann-La Roche | |
| Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | NCT00429026 | Renal Cell Canc... | Fludarabine Melphalan Cyclophosphamid... Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers | NCT01079286 | Renal Cell Canc... Cancer | Nelfinavir and ... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | NCT05263609 | Renal Cell Canc... | Axitinib Pembrolizumab | 18 Years - 99 Years | University of Oklahoma | |
| Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides | NCT02429440 | Renal Cell Canc... Advanced Renal ... | peptide vaccine Granulocyte Mac... Montanide ISA-5... | 18 Years - | University Hospital Tuebingen | |
| A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | NCT01865747 | Renal Cell Carc... | Cabozantinib ta... Everolimus (Afi... | 18 Years - | Exelixis | |
| A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | NCT00520403 | Renal Cell Canc... | bevacizumab [Av... Interferon alfa... Vinblastine | 18 Years - | Hoffmann-La Roche | |
| A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed | NCT03890731 | Solid Cancer | BAY73-4506 (Reg... | 18 Years - | Bayer | |
| A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | NCT00796757 | Renal Cell Canc... | bevacizumab [Av... interferon alfa... | 18 Years - | Hoffmann-La Roche | |
| Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer | NCT00079612 | Carcinoma, Rena... | Sorafenib (Nexa... Placebo | 18 Years - | Bayer | |
| Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis | NCT00172003 | Renal Cell Canc... Neoplasm Metast... | Zoledronic acid | 18 Years - | Novartis | |
| A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | NCT01021059 | Melanoma Carcinoma, Rena... | rh IL-15 | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| WIRE - Novel Treatments in Renal Cell Cancer | NCT03741426 | Renal Cell Canc... | Olaparib Cediranib Durvalumab | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Bevacizumab in Metastatic Renal Cancer | NCT02627144 | Renal Cell Canc... | Bevacizumab Interferon alph... | 18 Years - | Hoffmann-La Roche | |
| An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) | NCT01392729 | Renal Cell Canc... | 18 Years - | Hoffmann-La Roche | ||
| Tumor Registry of Advanced Renal Cell Carcinoma | NCT00610012 | Renal Cell Carc... | 18 Years - | iOMEDICO AG | ||
| Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | NCT00352859 | Carcinoma, Rena... | Nexavar (Sorafe... Gemcitabine or ... | 18 Years - | Bayer | |
| Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | NCT01189370 | Renal Cell Canc... | sorafenib | 18 Years - | University of Kansas Medical Center | |
| Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma | NCT00311467 | Renal Cell Canc... | Capecitabine, I... | 19 Years - 75 Years | Central European Cooperative Oncology Group | |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | NCT05433142 | Clear Cell Rena... | XmAb819 | 18 Years - | Xencor, Inc. | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention | NCT02375776 | Renal Cell Canc... Prostate Cancer Effects of Chem... | CORA- Device:sm... | 18 Years - | Massachusetts General Hospital | |
| Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients | NCT01507740 | Hepatocellular ... Non-small Cell ... Renal Cell Canc... Colorectal Canc... | Avastin Suntent Nexavar | 18 Years - | Medical University Innsbruck | |
| An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma | NCT01351571 | Renal Cell Canc... | 18 Years - | Hoffmann-La Roche | ||
| Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers | NCT03694912 | Clear Renal Cel... | Partial or radi... | 20 Years - | Yonsei University | |
| Study of CP-461 in Patients With Advanced Renal Cell Cancer | NCT00036036 | Renal Cell Carc... | CP-461 | 18 Years - | Astellas Pharma Inc | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | NCT04969315 | Renal Cell Canc... Castrate Resist... Non Small Cell ... Head and Neck S... | TT-10 | 18 Years - | Portage Biotech | |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | NCT05061537 | Renal Cell Canc... Melanoma Non-Small-Cell ... Hepatocellular ... Bladder Cancer Sarcoma Head and Neck C... Colorectal Canc... Ovarian Cancer Squamous Cell C... | PF-07263689 Sasanlimab | 18 Years - | Pfizer | |
| Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | NCT00068393 | Metastatic Rena... Renal Cell Carc... | Doxorubicin Gemcitabine G-CSF (granuloc... Neulasta | 18 Years - | Eastern Cooperative Oncology Group | |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | NCT02655822 | Renal Cell Canc... Metastatic Cast... | Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant | 18 Years - | Corvus Pharmaceuticals, Inc. | |
| Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | NCT00561912 | Renal Cell Carc... | Decitabine Interferon Alfa... | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland | NCT00980213 | Neoplasms Renal Cell Carc... | sunitinib | 18 Years - 85 Years | Tampere University Hospital | |
| Cellular Immunity and Renal Cell Cancer | NCT04377113 | NK Cell Mediate... NK Cell Cytokin... Kidney Cancer | 18 Years - | Clinical Hospital Center Rijeka | ||
| IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy. | NCT01967407 | Kidney Tumor Renal Cell Canc... | Irreversible El... | 18 Years - | University of Magdeburg | |
| Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | NCT00068393 | Metastatic Rena... Renal Cell Carc... | Doxorubicin Gemcitabine G-CSF (granuloc... Neulasta | 18 Years - | Eastern Cooperative Oncology Group | |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | NCT06362369 | Advanced Cancer Advanced Solid ... Melanoma Metastasis Pleural Mesothe... Renal Cell Carc... MSI-High Mismatch Repair... Colorectal Canc... Hepatocellular ... Hepatocellular ... Renal Cell Canc... Kidney Cancer Skin Cancer Non Small Cell ... NSCLC Anaplastic Lymp... ALK Genomic Tum... | Alintegimod Ipilimumab Nivolumab | 18 Years - | 7 Hills Pharma, LLC | |
| A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | NCT02684006 | Renal Cell Canc... | Avelumab (MSB00... Axitinib (AG-01... Sunitinib | 18 Years - | Pfizer | |
| A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer. | NCT00678288 | Carcinoma, Rena... | Sorafenib (Nexa... Sorafenib (Nexa... | 18 Years - | Bayer | |
| Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | NCT04620603 | Cutaneous Malig... Renal Cell Canc... Urothelial Canc... | Low Dose Rate B... Standard-of-Car... | 18 Years - | Case Comprehensive Cancer Center | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer | NCT00582790 | Kidney Cancer | IL2 Zoledronic acid | 18 Years - | University of Wisconsin, Madison | |
| A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | NCT02212730 | Renal Cell Canc... | Pembrolizumab P... Surgical Resect... Pembrolizumab P... | 18 Years - | Merck Sharp & Dohme LLC | |
| Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma | NCT04714697 | Renal Cell Canc... | Cabometyx | 19 Years - | Asan Medical Center | |
| Fecal Microbiota Transplantation in Diarrhea Induced by Tyrosine-kinase Inhibitors | NCT04040712 | Diarrhea Caused... Renal Cell Canc... | Donor FMT Sham FMT | 18 Years - | Catholic University of the Sacred Heart | |
| Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin | NCT00971620 | Cutaneous Leiom... Hereditary Leio... | Botulinum toxin... Placebo | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | NCT00520403 | Renal Cell Canc... | bevacizumab [Av... Interferon alfa... Vinblastine | 18 Years - | Hoffmann-La Roche | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome | NCT04625556 | Urological Mali... Prostate Cancer Renal Cell Canc... Bladder Cancer Ureter Cancer | 20 Years - | Yonsei University | ||
| Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | NCT00304460 | Metastatic Mela... Renal Cell Canc... | aldesleukin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| NANOTECH RCC Biomarkers | NCT02923284 | Renal Cell Carc... Renal Cell Canc... | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
